Population pharmacokinetics of ceftazidime in intensive care unit patients: Influence of glomerular filtration rate, mechanical ventilation, and reason for admission

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4483-4489

  Georges, Bernard ^a   Conil, Jean Marie ^a   Seguin, Thierry ^a   Ruiz, Stéphanie ^a   Minville, Vincent ^a   Cougot, Pierre ^a   Decun, Jean François ^a   Gonzalez, Hélène ^a   Houin, Georges ^b   Fourcade, Olivier ^a   Saivin, Sylvie ^a,b  

^a CHU RANGUEIL   (France)

^b Institut Federatif de Biologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOTRACHEAL INTUBATION; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; KIDNEY DISEASE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE TRAUMA; OPEN STUDY; PHARMACOLOGICAL PARAMETERS; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; VALIDATION PROCESS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; RESPIRATION, ARTIFICIAL;

EID: 70349315443     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00430-09     Document Type: Article

References (42)

1. Angus, B. J., M. D. Smith, Y. Suputtamongkol, H. Mattie, A. L. Walsh, V. Wuthiekanun, W. Chaowagul, and N. J. White. 2000. Pharmacokinetic- pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br. J. Clin. Pharmacol. 50:184-191.
2. Annat, G., J. P. Viale, B. Bui Xuan, O. Hadj Aissa, D. Benzoni, M. Vincent, C. Gharib, and J. Motin. 1983. Effect of PEEP ventilation on renal function, plasma renin, aldosterone, neurophysins and urinary ADH, and prostaglandins. Anesthesiology 58:136-141. (Pubitemid 13183930)
3. Beal, S. L., and L. B. Sheiner. 1982. Estimating population kinetics. Crit. Rev. Biomed Eng. 8:195-222.
4. Boeckmann, A., L. Sheiner, and S. Beal. 1994. NONMEM user's guide, part V. Introductory guide. NonMem Project Group, University of California, San Francisco.
5. Bookstaver, P. B., J. W. Johnson, T. P. McCoy, D. Stewart, and J. C. Williamson. 2008. Modification of diet in renal disease and modified Cockcroft-Gault formulas in predicting aminoglycoside elimination. Ann. Pharmacother. 42:1758-1765.
6. Buck, C., N. Bertram, T. Ackermann, T. Sauerbruch, H. Derendorf, and W. D. Paar. 2005. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int. J. Antimicrob. Agents 25:62-67.
7. Burgess, D. S., and C. R. Frei. 2005. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J. Antimicrob. Chemother. 56:893-898.
8. Cavallo, J. D., and A. Merens. 2008. Pseudomonas aeruginosa and betalactam antibiotics at the time of Europe. Pathol. Biol. (Paris) 56:435-438.
9. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
10. Conil, J. M., B. Georges, M. Lavit, J. Laguerre, K. Samii, G. Houin, and S. Saivin. 2007. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation. Br. J. Clin. Pharmacol. 64:27-35.
11. Dailly, E., M. Pannier, P. Jolliet, and M. Bourin. 2003. Population pharmacokinetics of ceftazidime in burn patients. Br. J. Clin. Pharmacol. 56:629-634.
12. De Ryke, C. A., J. L. Kuti, and D. P. Nicolau. 2007. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy 27:333-342.
13. Di Giantomasso, D., R. Bellomo, and C. N. May. 2005. The haemodynamic and metabolic effects of epinephrine in experimental hyperdynamic septic shock. Intensive Care Med. 31:454-462.
14. Duffull, S. B., M. J. Dooley, B. Green, S. G. Poole, and C. M. Kirkpatrick. 2004. A standard weight descriptor for dose adjustment in the obese patient. Clin. Pharmacokinet. 43:1167-1178.
15. Dufour, G., and P. Montravers. 2009. Pharmacokinetics of antibiotics or antifungal drugs in intensive care units. Curr. Infect. Dis. Rep. 11:14-20.
16. Gomez, C. M., J. J. Cordingly, and M. G. Palazzo. 1999. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob. Agents Chemother. 43:1798-1802.
17. Hoste, E. A., J. Damen, R. C. Vanholder, N. H. Lameire, J. R. Delanghe, K. Van den Hauwe, and F. A. Colardyn. 2005. Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. Nephrol. Dial. Transplant. 20:747-753.
18. James, W. 1976. Research on obesity: a report of the DMSS/MRC group. Her Majesty's Stationery Office, London, United Kingdom.
19. Kang, Y. S., K. H. Han, S. Y. Han, H. K. Kim, and D. R. Cha. 2005. Characteristics of population with normal serum creatinine impaired renal function and the validation of a MDRD formula in a healthy general population. Clin. Nephrol. 63:258-266.
20. Kirkpatrick, C. M., S. B. Duffull, and E. J. Begg. 1999. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br. J. Clin. Pharmacol. 47:637-643.
21. Levey, A. S., J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, D. Roth, et al. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Intern. Med. 130:461-470.
22. Lipman, J., S. C. Wallis, and R. J. Boots. 2003. Cefepime versus cefpirome: the importance of creatinine clearance. Anesth. Analg. 97:1149-1154.
23. Ljungberg, B., and I. Nilsson-Ehle. 1989. Advancing age and acute infection influence the kinetics of ceftazidime. Scand. J. Infect. Dis. 21:327-332.
24. Luthy, R., J. Blaser, A. Bonetti, H. Simmen, R. Wise, and W. Siegenthaler. 1981. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob. Agents Chemother. 20:567-575.
25. Marik, P. E. 1993. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth. Intensive Care 21:172-173. (Pubitemid 23132762)
26. Meagher, A. K., A. Forrest, C. R. Rayner, M. C. Birmingham, and J. J. Schentag. 2003. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob. Agents Chemother. 47:548-553.
27. Mouton, J. W., and J. G. den Hollander. 1994. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 38:931-936.
28. Mouton, J. W., A. M. Horrevorts, P. G. Mulder, E. P. Prens, and M. F. Michel. 1990. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob. Agents Chemother. 34:2307-2311.
29. Mouton, J. W., N. Punt, and A. A. Vinks. 2005. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin. Ther. 27:762-772.
30. Poggio, E. D., X. Wang, D. M. Weinstein, N. Issa, V. W. Dennis, W. E. Braun, and P. M. Hall. 2006. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am. J. Transplant. 6:100-108.
31. Robert, S., B. J. Zarowitz, E. L. Peterson, and F. Dumler. 1993. Predictability of creatinine clearance estimates in critically ill patients. Crit. Care Med. 21:1487-1495.
32. Roberts, J. A., J. Paratz, E. Paratz, W. A. Krueger, and J. Lipman. 2007. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int. J. Antimicrob. Agents 30:11-18.
33. Roos, J. F., J. Lipman, and C. M. Kirkpatrick. 2007. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Med. 33:781-788.
34. Sheiner, L. B., and S. L. Beal. 1981. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9:503-512.
35. Sommers, D. K., L. Walters, M. Van Wyk, S. M. Harding, A. M. Paton, and J. Ayrton. 1983. Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob. Agents Chemother. 23:892-896.
36. Swart, E. L., K. P. Zuideveld, J. de Jongh, M. Danhof, L. G. Thijs, and R. M. Strack van Schijndel. 2004. Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br. J. Clin. Pharmacol. 57:135-145.
37. Thomas, L., and A. R. Huber. 2006. Renal function - estimation of glomerular filtration rate. Clin. Chem. Lab. Med. 44:1295-1302.
38. Tod, M., C. Padoin, C. Minozzi, J. Cougnard, and O. Petitjean. 1996. Population pharmacokinetic study of isepamicin with intensive care unit patients. Antimicrob. Agents Chemother. 40:983-987.
39. Townsend, P. L., M. P. Fink, K. L. Stein, and S. G. Murphy. 1989. Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients. Crit. Care Med. 17:154-157.
40. Triginer, C., R. Fernandez, I. Izquierdo, J. Rello, and S. Benito. 1989. Gentamicin pharmacokinetic changes related to mechanical ventilation. DICP 23:923-924. (Pubitemid 19284819)
41. van Dalen, R., and T. B. Vree. 1990. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med. 16(Suppl. 3):S235-S238.
42. Young, R. J., J. Lipman, T. Gin, C. D. Gomersall, G. M. Joynt, and T. E. Oh. 1997. Intermittent bolus dosing of ceftazidime in critically ill patients. J. Antimicrob. Chemother. 40:269-273.